Executive VP Pharmaceutical and Business Operations · Unicycive Therapeutics, Inc. (UNCY)

Pramod Gupta

A named executive officer of Unicycive Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,155,271

Salary $468,000Bonus $222,300

FY2023: $1,523,229

2nd of 3 named executive officers at Unicycive Therapeutics by FY2024 total.

3 named officers on file for Unicycive Therapeutics, FY2024

Pramod Gupta’s pay file — $29

  • 5 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Unicycive Therapeutics’s whole pay program stands against its peers

  • Unicycive Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on UNCY→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Pramod Gupta’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Pramod Gupta compensation by year

Unicycive Therapeutics Summary Compensation Table · all 5 fiscal years held
In US dollars, as Unicycive Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023FY2024
Salary$0$187,500$450,000$450,000$468,000
Bonus$0$0$329,178$225,000$222,300
Stock awards$0$0$0——
Option awards$212,250$231,555$17,491$859,479$464,971
Non-equity incentive$0$0$0——
Pension and deferred compensation$0$0$0——
All other$60,000$68,750$0$0$0
Total$272,250$487,805$796,669$1,523,229$1,155,271

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Unicycive Therapeutics, Inc. DEF 14A filed April 30, 2025, accession 0001213900-25-037613, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Unicycive Therapeutics, Inc. filed document, accession 0001213900-25-037613. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2025.

$272K
$488K
$797K
$1.5M
$1.2M
FY20
FY21
FY22
FY23
FY24
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option42,344—$7.50
Option27,024—$11.40
Option5,450—$3.40
Option90,000—$4.71
Option642—$7.50

Per the Outstanding Equity Awards at Fiscal Year-End table in Unicycive Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

3 Form 4 lines since the FY2024 proxy (filed April 30, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-05-14Grant or award derivative—169,500$0.00169,500
2026-05-14Grant or award derivative—169,500$0.00169,500
2025-07-28Grant or award derivative—90,000$0.00301,986

The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments Unicycive Therapeutics discloses, by trigger · FY2025
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$702,000$114,000—$816,000
Change in control and involuntary termination$702,000$114,000—$816,000

Per the Potential Payments Upon Termination or Change in Control table in Unicycive Therapeutics, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.

Unicycive Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Shalabh GuptaChief Executive Officer$2,439,884
Pramod Gupta · this pageExecutive VP Pharmaceutical and Business Operations$1,155,271
Doug JermasekExecutive VP, Corporate Strategy$873,346

The full Unicycive Therapeutics compensation record

free company brief

This page is one person within Unicycive Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Unicycive Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Pramod Gupta's compensation dossier · One-time report. No refunds.